IDYA is expected to report earnings to fall 5.34% to -64 cents per share on November 13
Q3'24
Est.
$-0.64
Q2'24
Missed
by $0.14
Q1'24
Missed
by $0.02
Q4'23
Missed
by $0.05
Q3'23
Beat
by $0.03
The last earnings report on August 06 showed earnings per share of -68 cents, missing the estimate of -53 cents. With 721.17K shares outstanding, the current market capitalization sits at 2.60B.
an oncology-focused precision medicine company committed to the discovery and development of targeted cancer therapeutics for patient populations selected using molecular diagnostics.